

attachments may be formatted as WordPerfect 5.0, 5.1/5.2, 6.0/6.1, or ASCII files.

Information can also be obtained by calling 1-800-35-NIOSH or by the Internet NOISH Homepage: <http://www.cdc.gov/noish/homepage.html>.

Dated: May 14, 1996.

Nancy C. Hirsch,

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 96-12557 Filed 5-17-96; 8:45 am]

BILLING CODE 4160-19-M

### Food and Drug Administration

[Docket No. 96F-0145]

#### Albright & Wilson, Ltd.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that Albright & Wilson, Ltd., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of tetrakis(hydroxymethyl)phosphonium sulfate as a slimicide for use in the manufacture of paper and paperboard intended to contact food.

**DATES:** Written comments on the petitioner's environmental assessment by June 19, 1996.

**ADDRESSES:** Submit written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.

**FOR FURTHER INFORMATION CONTACT:** Daniel N. Harrison, Center for Food Safety and Applied Nutrition (HFS-216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204-0002, 202-418-3080.

**SUPPLEMENTARY INFORMATION:** Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 5B4472) has been filed by Albright & Wilson, Ltd., c/o Delta Analytical Corp., 7910 Woodmont Ave., suite 1000, Bethesda, MD 20814. The petition proposes to amend the food additive regulations in § 176.300 *Slimicides* (21 CFR 176.300) to provide for the safe use of tetrakis(hydroxymethyl)phosphonium sulfate as a slimicide in the manufacture of paper and paperboard intended to contact food.

The potential environmental impact of this action is being reviewed. To

encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before June 19, 1996, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the Federal Register. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the Federal Register in accordance with 21 CFR 25.40(c).

Dated: April 30, 1996.

Alan M. Rulis,

*Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.*

[FR Doc. 96-12568 Filed 5-17-96; 8:45 am]

BILLING CODE 4160-01-F

[Docket No. 93F-0152]

#### Witco Corp.; Withdrawal of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to future filing, of a food additive petition (FAP 3B4348), filed by Witco Corp. proposing that the food additive regulations be amended to provide for the safe use of decanedioic acid, polymer with 1,2-ethanediamine, (Z,Z)-9,12-octadecadienoic acid dimer and 4,4'-(1,3-propaneidyl) bis(piperidine) as a polymer coating on aluminum foil, polyolefin film, and paper and paperboard and as an adhesive, for use in contact with food.

**FOR FURTHER INFORMATION CONTACT:** Hortense S. Macon, Center for Food Safety and Applied Nutrition (HFS-216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-418-3086.

**SUPPLEMENTARY INFORMATION:** In a notice published in the Federal Register of May 19, 1993 (58 FR 29231), FDA announced that a food additive petition (FAP 3B4348) had been filed by Witco Corp., 5777 Frantz Rd., P.O. Box 646, Dublin, OH 43017. The petition proposed to amend the food additive regulations to provide for the safe use of decanedioic acid, polymer with 1,2-ethanediamine, (Z,Z)-9,12-octadecadienoic acid dimer and 4,4'-(1,3-propaneidyl) bis(piperidine) as a polymer coating on aluminum foil, polyolefin film, and paper and paperboard and as an adhesive, for use in contact with food. Witco Corp. has now withdrawn the petition without prejudice to a future filing (21 CFR 171.7).

Dated: April 30, 1996.

Alan M. Rulis,

*Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.*

[FR Doc. 96-12567 Filed 5-17-96; 8:45 am]

BILLING CODE 4160-01-F

[Docket No. 96N-0151]

#### SmithKline Beecham Pharmaceuticals; Withdrawal of Approval of a New Drug Application for Selacryn® Tablets

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is withdrawing approval of a new drug application (NDA) for Selacryn® (ticrynafen) Tablets held by SmithKline Beecham Pharmaceuticals (SmithKline). SmithKline requested that the NDA be withdrawn because the product is no longer being marketed. SmithKline also waived its opportunity for a hearing. **EFFECTIVE DATE:** May 20, 1996.

**FOR FURTHER INFORMATION CONTACT:** Lola E. Batson, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-1038.

**SUPPLEMENTARY INFORMATION:** By letter dated June 30, 1994, SmithKline, Four Falls Corp. Center, Route 23 and Woodmont Ave., P.O. Box 1510, FF0410, King of Prussia, PA 19406, requested that FDA withdraw NDA 18-103 for Selacryn® (ticrynafen) Tablets, stating that the company discontinued

marketing the product in 1980 because of liver toxicity observed after approval of the NDA. SmithKline waived its opportunity for a hearing.

Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82), approval of NDA 18-103, and all amendments and supplements thereto, is hereby withdrawn effective May 20, 1996.

Dated: May 6, 1996.  
Murray M. Lumpkin,  
Deputy Director, Center for Drug Evaluation  
and Research.  
[FR Doc. 96-12570 Filed 5-15-96; 8:45 am]  
BILLING CODE 4160-01-F

#### Health Care Financing Administration

##### Agency Information Collection Activities: Proposed Collection; Comment Request

AGENCY: Health Care Financing  
Administration.

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Health Care Financing Administration (HCFA), Department of Health and Human Services, is publishing the following summaries of proposed collections for public comment. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

1. *Type of Information Collection*  
*Request:* New Collection; *Title of Information Collection:* Evaluation of the Oregon Medicaid Reform Demonstration: Adult Interview, Child Interview, Pediatric Asthma Interview, Insulin-Dependent Diabetes Interview, Low Back Pain Interview, Medical Provider Questionnaire; *Form No.:* HCFA-R-192; *Use:* The survey instruments listed above are for use in the Evaluation of the Oregon Medicaid Reform Demonstration. The Adult and Child Interviews are designed to collect information related to health status, access to care, satisfaction with care and

past health insurance status for adult and child members of the Oregon Health Plan (OHP). The Pediatric Asthma Interview, Insulin-Dependent Diabetes Interview and Low Back Pain Interview collect information on quality of care, utilization of care, satisfaction with care and health status of OHP members with selected "tracer conditions." The Medical Provider Questionnaire is designed to collect information on how both participating and non-participating physicians view OHP; *Frequency:* Biennially, Other (one time); *Affected Public:* Not-for-profit institutions, individuals and households, business or other for-profit; *Number of Respondents:* 22,229; *Total Annual Hours:* 3,070.

2. *Type of Information Collection*  
*Request:* New Collection; *Title of Information Collection:* Evaluation of the Per-Episode Home Health Prospective Payment Demonstration; *Form No.:* HCFA-R-195; *Use:* This evaluation will collect primary data from samples of patients and from demonstration agencies to assess impacts of per-episode payment on access to care, quality of care, and the use of non-Medicare services; *Frequency:* Other (one time); *Affected Public:* Not-for-profit institutions, individuals and households, business or other for-profit; *Number of Respondents:* 19,191; *Total Annual Hours:* 1,901.

3. *Type of Information Collection*  
*Request:* Extension of a currently approved collection; *Title of Information Collection:* Blood Bank Inspection Checklist and Report; *Form No.:* HCFA-282; *Use:* The blood bank inspection checklist instrument is used by the State agency to record data collected as part of the survey and certification process to determine compliance with the requirement for blood bank services under Clinical Laboratory Improvement Amendments; *Frequency:* Biennially; *Affected Public:* State, local, and tribal government, business or other for-profit, not-for-profit institutions, federal government; *Number of Respondents:* 2,500; *Total Annual Hours:* 1,250.

To obtain copies of the supporting collection for the proposed paperwork collections referenced above, access HCFA's WEB SITE ADDRESS at <http://www.ssa.gov/hcfa/hcfahp2.html>, or to obtain the supporting statement and any related forms, E-mail your request, including your address and phone number, to [Paperwork@hcfa.gov](mailto:Paperwork@hcfa.gov), or call the Reports Clearance Office on (410) 786-1326. Written comments and recommendations for the proposed information collections must be mailed

within 60 days of this notice directly to the HCFA Paperwork Clearance Officer designated at the following address: HCFA, Office of Financial and Human Resources, Management Planning and Analysis Staff, Attention: John Burke, Room C2-26-17, 7500 Security Boulevard, Baltimore, Maryland 21244-1850.

Dated: May 13, 1996.  
Kathleen B. Larson,  
Director, Management Planning and Analysis  
Staff, Office of Financial and Human  
Resources, Health Care Financing  
Administration.  
[FR Doc. 96-12527 Filed 5-17-96; 8:45 am]  
BILLING CODE 4120-03-P

#### National Institutes of Health

##### National Institute on Deafness and Other Communication Disorders; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, amended (5 United States Code ... Appendix 2), notice is hereby given of the following meeting:

*Name of Committee:* Communication Disorders Review Committee.  
*Date:* June 5-7, 1996.  
*Time:* 8 am-5:30 pm, June 5; 8 am-5:30 pm, June 6; 8 am-adjournment, June 7.  
*Place:* Doubletree Hotel, 1750 Rockville Pike, Rockville MD 20852.  
*Contact Person:* Craig A. Jordan, Ph.D., Scientific Review Administrator, NIDCD/DEA/SRB, EPS Room 400C, 6120 Executive Boulevard, MSC 7180, Bethesda MD 20892-7180, 301-496-8683.  
*Purpose/Agenda:* To review and evaluate grant applications. The meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, United States Code. The applications and/or proposals and the discussion could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which could constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program No. 93.173 Biological Research Related to Deafness and Communication Disorders)

Dated: May 10, 1996.  
Susan K. Feldman,  
Committee Management Officer, NIH.  
[FR Doc. 96-12503 Filed 5-17-96; 8:45 am]  
BILLING CODE 4140-01-M

##### National Cancer Institute; Notice of Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as

may  
FORMAT  
for J

**SMITH KLINE & FRENCH LABORATORIES**

1500 Spring Garden St. P.O. Box 7029, Philadelphia, PA 19101 • 215-385-4000

Telex SMITH-KLINE PHILADELPHIA PA  
 • Telex 83-4487

January 16, 1980

URGENT: DRUG RECALL

Dear Doctor:

Clinical use of Selacryn<sup>®</sup> (brand of ticrynafen) has shown that the drug can cause significant hepatic injury. The injury is of the hepatocellular type. The 52 reports received thus far have been characterized by fever and elevation of serum transaminase levels, with jaundice in about 60% of these cases. A few instances of severe hepatic damage and death have been noted, but no definite causal relationship to 'Selacryn' administration has yet been established in these cases. No precise incidence figure for this adverse effect is available; the 52 reports have arisen in an exposed population of about 300,000 patients, which would represent an incidence of about 1 in 5,000. However, this is likely to be an underestimate as adverse effects tend to be underreported.


Because alternative treatments for hypertension and congestive heart failure are available, sale of 'Selacryn' has been suspended.

YOU SHOULD DISCONTINUE USE OF 'SELACRYN' IMMEDIATELY AND CONTACT PATIENTS WHO HAVE BEEN GIVEN 'SELACRYN'.

If a patient has symptoms that could suggest hepatic injury (fever, malaise, nausea, abdominal pain), assessment of liver function is appropriate. Any significant findings should be reported to us to assist in determining the frequency of hepatic injury. You may wish to evaluate liver function even in the absence of symptoms.

Commercial supplies of the drug are being recalled from retail and hospital pharmacies and wholesalers.

Sincerely,



Philip J. Tannenbaum, M.D.  
 Vice-President & Medical Director-U.S.

PJT:scd

**SMITH KLINE & FRENCH LABORATORIES**

1600 Spring Garden St. P.O. Box 7929, Philadelphia, PA 19101 • 215-381-4000

Tablet SMITHKLINE PHILADELPHIA PA  
Telex 33-4487

January 16, 1980

URGENT: DRUG RECALL

Dear Pharmacist:


Smith Kline & French Laboratories is recalling Selacryn® (brand of ticrynafen). You will be contacted shortly with specific details about procedures to be followed for the recall.

The enclosed letter is being sent to physicians in your community. It reports the occurrence of a hypersensitivity reaction involving the liver which has prompted the decision to suspend sale of 'Selacryn'.

We have alerted you in the hope that you may assist clinics, outpatient departments, and other areas of your hospital in identifying 'Selacryn' patients. The physician can then contact the patient and take appropriate steps.

Thank you for your attention and cooperation.

Sincerely,



Joseph L. Rutledge  
Vice President, Trade Relations

JLR:ctap  
Enclosure